Pancreatic Cancer Treatment β V2 Update
Treatment Walkthrough, Supportive Care & Singapore Medical Field Contributions Β· Updated 14 July 2026
π V2 β Updated with friend's latest surgical findings
π₯ HK treatment + SG support pathways
π¬ 30+ sources cited
β οΈ MEDICAL DISCLAIMER
This report is for informational purposes only and does NOT constitute medical advice. The patient must consult with qualified oncologists for all diagnosis and treatment decisions. Every case is unique and general statistics do not predict individual outcomes. All treatment decisions should be made with the patient's medical team. TCM and complementary therapies should only be used alongside (not instead of) conventional treatment, and only with the oncologist's knowledge and approval.
π What's New in V2
- Surgical findings updated: Cancer has spread beyond the pancreatic tail. Umbilical cyst confirmed cancerous β this means peritoneal spread is confirmed, not just suspected.
- Treatment plan confirmed: 6 months intensive chemotherapy (every 2 weeks Γ 12 cycles). Port catheter device implanted in shoulder + neck incision for home infusion. Surgery deferred.
- New sections added: Detailed treatment walkthrough, supportive care (medical/TCM/other), Singapore medical field contributions, and mainland China medical capabilities including CAR-T therapy breakthrough.
Quick Summary β Key Takeaways
- The situation: Pancreatic ductal adenocarcinoma (PDAC) at the tail of the pancreas, now confirmed to have spread to the peritoneum (umbilical cyst = Sister Mary Joseph nodule, biopsy-confirmed cancer). Surgery to remove the pancreatic tumor has been deferred β the priority is now systemic chemotherapy to control the spread.
- The treatment plan: 6 months of intensive chemotherapy, every 2 weeks (12 cycles total). Each cycle = clinic infusion + 48-hour home infusion via elastomeric pump connected to an implanted port catheter. White blood cell boosters (G-CSF) will be administered to protect the immune system.
- The strategy is sound: "Conversion chemotherapy" β shrinking tumors first, then reassessing surgery β is an established approach. Studies show FOLFIRINOX can make previously unresectable tumors operable in up to 60% of locally advanced cases. source
- Supportive care is critical: Nutrition, immune support, side effect management, and psychological well-being during 6 months of intensive chemo are just as important as the chemo itself. TCM, when integrated with oncologist approval, can help manage side effects.
- Singapore's role: Second opinion from NCCS SPRinT team (peritoneal specialists), PIPAC evaluation, clinical trial access, molecular profiling, integrative oncology support, and TCM cancer care β all available from Singapore.
1 Β· Updated Situation β What We Now Know
Critical update: The umbilical cyst (1.5 cm) removed during Part 1 of surgery was biopsied and confirmed cancerous. This means the cancer has spread beyond the pancreas to the peritoneal/abdominal wall. The surgeon correctly did NOT proceed with the pancreatic tumor removal β with confirmed metastatic spread, systemic treatment (chemotherapy) must come first to address all cancer sites simultaneously.
What the Belly Button Cyst Means
The 1.5 cm cyst in the belly button (umbilicus) is what medical literature calls a Sister Mary Joseph nodule β cancer cells that have spread from the abdominal cavity to the umbilical area. The biopsy confirming it as cancer definitively establishes that this is metastatic pancreatic cancer with peritoneal spread. This is no longer "micrometastatic" or suspected β it is confirmed. source
Why Surgery Was Deferred β And Why That's the Right Call
When cancer has spread beyond the primary organ, removing the primary tumor alone does not help β the cancer is elsewhere too. The standard approach in this situation is systemic chemotherapy first to:
- Attack cancer cells everywhere in the body (pancreas, peritoneum, umbilical site)
- Shrink the primary pancreatic tumor and the metastatic deposits
- Assess how well the cancer responds to treatment
- Potentially make the tumor operable later (conversion therapy)
Reason for hope: This is called
"conversion chemotherapy" β and it works. Studies show that after FOLFIRINOX treatment, previously unresectable pancreatic tumors became operable in up to
60% of cases. Even in metastatic disease, patients who respond to chemo and then undergo surgery show significantly improved survival (median OS 38.9 months vs 11.1 months for non-surgical patients).
source Β·
source
2 Β· How the Treatment Will Be Conducted
The Device Implantation Surgery (Day 2)
The second surgery (tomorrow, ~noon) involves two components:
| Component | What It Is | Purpose |
|---|
| Port catheter (shoulder) |
An implantable port (Port-a-Cath or similar) is placed under the skin of the upper chest/shoulder area. A thin flexible catheter tube is tunneled under the skin and threaded into a large vein near the collarbone. source |
Provides permanent IV access for chemotherapy without needing a new needle stick each time. The port stays in for the entire 6-month treatment. Nurses access it through the skin with a special needle. |
| Neck incision |
A small incision in the neck to position the catheter tip correctly in the superior vena cava (the large vein leading to the heart). |
Ensures chemotherapy drugs are delivered directly into the bloodstream where they can be rapidly distributed throughout the body. This is standard port placement technique. |
About the port: Once healed, the port is barely visible β just a small bump under the skin. It's waterproof (can shower/swim once healed), low-maintenance, and needs only periodic flushing. Most patients adjust to it within a few days.
source
The Chemotherapy Cycle β What Happens Every 2 Weeks
Based on the described protocol (clinic + 48-hour home infusion), the regimen is almost certainly FOLFIRINOX or modified FOLFIRINOX β the standard first-line treatment for metastatic pancreatic cancer in fit patients. Here's what each cycle looks like:
Day 1 β Clinic Visit (Oncologist's Clinic, Central)
~4-6 hours at clinic
- Blood tests β Check white blood cell count, kidney/liver function before each cycle. If counts are too low, the cycle may be delayed.
- Port accessed β Nurse connects the port to the IV line
- Oxaliplatin (IV infusion, ~2 hours) β A platinum-based chemo drug. Can cause cold sensitivity (neuropathy) β avoid cold drinks/objects for several days.
- Irinotecan (IV infusion, ~90 minutes) β Topoisomerase inhibitor. Can cause acute cholinergic syndrome (sweating, cramps, diarrhea) β atropine is given to prevent this.
- Leucovorin (IV infusion, ~2 hours) β Vitamin-like substance that enhances 5-FU effectiveness.
- 5-FU bolus (IV push, ~5 minutes) β Quick dose of fluorouracil
- Home pump connected β An elastomeric pump (small balloon device, ~500g) is attached to the port. It will slowly deliver 5-FU continuously over the next 46-48 hours. source Β· source
Days 1-3 β Home Infusion (48 Hours)
At home with the pump
- The elastomeric pump is a small, lightweight device worn in a pouch/bag. It doesn't need batteries β it works by balloon pressure, delivering chemo at a steady rate automatically.
- The patient does not need to do anything except keep the pump clean, dry, and at body temperature (wear it against skin, not outside clothing in cold weather).
- Keep the pump at the same height as your heart for correct flow rate β don't hang it up or let it dangle.
- The pump runs for 46-48 hours and stops automatically when the balloon is empty. You'll see wrinkles in the balloon when it's done. source
- After 48 hours: Return to clinic β nurse disconnects the pump and flushes the port. This is a quick visit (~30 min).
Caregiver tips for home infusion: Keep a log of any symptoms. Don't get the pump site wet (sponge baths OK, no full shower until port is covered properly). Avoid strenuous activity. Have anti-nausea medications ready. Call the oncologist's 24-hour hotline if: fever β₯38Β°C, severe diarrhea, severe vomiting, pain at port site, pump appears to be running too fast/slow, or the line disconnects.
Days 3-14 β Recovery & Immune Support at Home
~12 days between cycles
- White blood cell booster (G-CSF): Pegfilgrastim (Neulasta) injection β usually given ~24-48 hours after chemo ends. A single injection that stimulates bone marrow to produce white blood cells, protecting against infection during the neutropenic window (days 5-10 when white cells are lowest). source
- Nadir period (days 7-10): White blood cells, red blood cells, and platelets are at their lowest. Avoid crowds, sick people, raw foods. Monitor temperature daily. Any fever β₯38Β°C = emergency β go to hospital immediately.
- Side effects typically peak days 3-7 then gradually improve. By day 10-12, most patients feel reasonably normal again before the next cycle.
- Day 14: Return to clinic for the next cycle. Blood tests first β if counts are adequate, the next cycle proceeds.
The Full 6-Month Timeline
| Period | What Happens | Key Milestones |
|---|
| Week 0 (now) | Two surgeries: umbilical cyst removal (done), port implantation (tomorrow) | Wound healing begins |
| Weeks 1-2 | Recovery from surgeries. No chemo yet β wounds must heal first. | Surgical wounds close; port site heals |
| Week 2 | Chemo Cycle 1 begins | Baseline CT scan; CA 19-9 blood marker measured |
| Weeks 2-26 | 12 cycles of chemotherapy, every 2 weeks | CT scans every 8-9 weeks (after every 4th cycle) to assess response |
| ~Week 10 (after Cycle 4) | First response assessment β CT scan + CA 19-9 comparison | Is the tumor shrinking? Is the SMJ nodule resolved? Adjust treatment if needed |
| ~Week 18 (after Cycle 8) | Second response assessment | Decision point: continue same regimen? Switch? Consider surgery? |
| ~Week 26 (after Cycle 12) | Final assessment β comprehensive CT/PET-CT | Conversion surgery decision: Has the tumor shrunk enough to operate? Are metastatic deposits gone? |
| Post-chemo | Either: surgery (if tumor is now resectable), maintenance therapy, or different treatment approach | The 6-month chemo results determine the next phase |
Understanding the strategy: The friend's oncologist is following the
"conversion therapy" approach β the most aggressive and potentially curative path for metastatic PDAC. The goal is to use chemotherapy to: (1) kill cancer cells throughout the body, (2) shrink the pancreatic tumor enough to make it operable, (3) eliminate or control peritoneal spread. If imaging after 6 months shows the tumor is resectable and metastatic disease is controlled, surgery becomes an option. This is the best-case scenario and it does happen β in ~60% of locally advanced cases after FOLFIRINOX.
source
What "White Hemoglobin" Injection Means
The friend mentioned injecting "white hemoglobin" to boost the immune system. This almost certainly refers to G-CSF (Granulocyte Colony-Stimulating Factor) β specifically pegfilgrastim (Neulasta) or filgrastim (Neupogen):
- What it does: Stimulates bone marrow to produce white blood cells (neutrophils) rapidly, replacing those destroyed by chemotherapy
- Why it's needed: FOLFIRINOX is aggressive β it drops white blood cell counts significantly (neutropenia). Without G-CSF support, patients are vulnerable to serious infections during the nadir period (days 5-10 post-chemo)
- Pegfilgrastim = one injection per cycle (long-acting, given ~24 hours after chemo). Filgrastim = daily injections for 5-7 days (short-acting). source
- Side effects: Mild bone pain (most common β ~34% of patients), can be managed with paracetamol source
- Cost: Pegfilgrastim is expensive (~USD 3,000-6,000 per injection without insurance) β check insurance coverage
3 Β· Side Effects β What to Expect & How to Manage
Knowing what's coming helps reduce anxiety and allows preparation. Side effects vary by individual β some sail through, others struggle more. Most are manageable with medication and lifestyle adjustments. source Β· source
Common Side Effects of FOLFIRINOX
| Side Effect | When | Management |
|---|
| Nausea & Vomiting | Days 1-3, worst on infusion day | Anti-emetics (ondansetron, aprepitant, dexamethasone) given before and after chemo. Eat small frequent meals. Avoid strong-smelling foods. Ginger tea helps. |
| Diarrhea | Days 2-5 (irinotecan-induced) | Loperamide (Imodium) β start at first sign. Hydration critical (electrolyte drinks). Avoid dairy, high-fiber, spicy foods during episodes. Severe diarrhea = call oncologist immediately (can be life-threatening with irinotecan) |
| Fatigue | Progressive β accumulates over cycles | Most common side effect. Rest when needed but gentle exercise (short walks) actually helps. Don't push through. Prioritize sleep. Anemia may contribute β check blood counts. |
| Peripheral neuropathy | Days 1-7 after each cycle (oxaliplatin) | Cold sensitivity β avoid cold drinks, cold air, touching cold objects for ~1 week after infusion. Wear gloves when reaching into the fridge. This is a hallmark of oxaliplatin. Usually reversible but can persist. Report worsening to oncologist. |
| Neutropenia (low white cells) | Nadir days 7-10 | G-CSF injections. Avoid crowds, sick contacts, raw food (sushi, raw eggs, unpasteurized dairy). Temperature monitoring daily. Fever β₯38Β°C = medical emergency. |
| Mouth sores (mucositis) | Days 5-10 | Salt water rinses. Soft, cool foods. Avoid alcohol-based mouthwashes. "Magic mouthwash" (lidocaine+antacid+antihistamine) can help. Good oral hygiene before chemo starts. |
| Hair thinning | After cycle 2-3 | Usually thinning, not total loss (unlike other chemo regimens). Reversible after treatment ends. Cold caps can reduce this but are uncomfortable. |
| Loss of appetite | Throughout | Small frequent meals. Nutritional supplements (Ensure, Fortisip). Eat calorie-dense foods when you can eat. Pancreatic enzyme replacement (Creon) if malabsorption occurs. |
| Taste changes | Throughout | Food may taste metallic. Use plastic utensils. Marinate meats in sweet/sour sauces. Cold foods often taste better than hot. |
When to call the oncologist immediately (24-hour hotline):
- Fever β₯38Β°C (single reading) or β₯37.5Β°C lasting >1 hour
- Severe diarrhea (>7 episodes/day) or diarrhea with blood
- Vomiting that prevents keeping any fluids down for >12 hours
- Severe abdominal pain
- Signs of infection: redness, swelling, warmth at any site
- Unusual bleeding or bruising
- Difficulty breathing or chest pain
- Port site: redness, swelling, pain, or drainage
4 Β· Medical Supportive Care β What We Can Do
Supportive care is not optional β it's an integral part of cancer treatment. Good supportive care directly improves chemo tolerance, allows full dose intensity (not having to reduce doses), and improves outcomes. source
4.1 Nutrition β The Foundation
Pancreatic cancer + chemotherapy create a triple nutritional challenge: (1) the tumor alters metabolism, (2) the pancreas may not produce enough enzymes for digestion, (3) chemo causes nausea/diarrhea/loss of appetite. Weight loss is the enemy β patients who maintain weight tolerate chemo better and have better outcomes.
Key Nutritional Strategies
| Strategy | Details |
|---|
| Pancreatic enzyme replacement (PERT) | If the pancreatic tail tumor or surgery has reduced enzyme production, Creon (pancrelipase) capsules with every meal help digest fats/proteins. Symptoms of need: floating/fatty stools, weight loss despite eating. Discuss with oncologist. source |
| High-protein, high-calorie diet | Aim for 1.2-1.5g protein per kg body weight daily. Small frequent meals (6-8 per day). Nutritional supplement drinks (Ensure, Fortisip, Resource) β 2-3 bottles/day between meals. source |
| Maintain hydration | 2-3 liters fluid/day (water, electrolyte drinks, broth, weak tea). Dehydration worsens fatigue and kidney function. Avoid alcohol and excessive caffeine. |
| Vitamin supplementation | B12 (if deficient β common in pancreatic disease), Vitamin D (most cancer patients are deficient), iron (if anemic). Always discuss supplements with oncologist first β some antioxidants can interfere with chemo. |
| Food safety during nadir | When white blood cells are low (days 5-10 post-chemo): NO raw fish/sushi, raw eggs, unpasteurized dairy, unwashed fruits/veg, deli meats. Cook everything thoroughly. source |
4.2 Immune System Support
| Intervention | Details |
|---|
| G-CSF injections | As described above β pegfilgrastim or filgrastim. This is the primary medical intervention for neutropenia prevention. Critical for FOLFIRINOX patients. source |
| Infection prevention | Hand hygiene (alcohol gel), avoid crowds during nadir, wear mask in clinics/hospitals, avoid contact with sick people, avoid gardening (soil bacteria), no cat litter boxes (Toxoplasma risk). |
| Vaccinations | Flu vaccine (inactivated only β no nasal spray), COVID-19 vaccine/boosters, pneumococcal vaccine. Discuss timing with oncologist β best given before chemo starts or during recovery period. |
| Red blood cell support | If anemia develops: iron supplements, erythropoietin injections (EPO), or blood transfusions if severe. Fatigue from anemia is treatable. |
| Platelet monitoring | If platelets drop too low, chemo may need dose reduction. Report easy bruising/bleeding gums. |
4.3 Symptom Management Medications
| Symptom | Medications |
|---|
| Nausea | Ondansetron (Zofran), Aprepitant (Emend), Dexamethasone, Metoclopramide. Usually given as a combination protocol before and after chemo. |
| Diarrhea | Loperamide (Imodium) β carry at all times. For irinotecan-related: atropine for acute symptoms, loperamide for delayed. Octreotide for severe cases. |
| Constipation | Common from anti-nausea drugs. Senna, lactulose, PEG (Miralax). Increase fluids and fiber when not having diarrhea. |
| Neuropathy | Pregabalin (Lyrica), Gabapentin. Avoid cold exposure. Report worsening β may need oxaliplatin dose reduction. |
| Pain | Paracetamol first line. Stronger pain: discuss with oncologist (tramadol, morphine if needed). Avoid NSAIDs (ibuprofen, naproxen) β bleeding risk with low platelets. |
| Anxiety/Insomnia | Lorazepam (short-term), sleep hygiene, meditation apps. Don't suffer in silence β tell the oncologist. |
| Mucositis | "Magic mouthwash" (viscous lidocaine + Maalox + diphenhydramine). Salt water rinses. Palifermin for severe cases. |
4.4 CA 19-9 Tumor Marker Monitoring
CA 19-9 is a blood tumor marker for pancreatic cancer. It's measured before each chemo cycle and tracked over time:
- Rising CA 19-9 = cancer may be growing β treatment may need adjustment
- Falling CA 19-9 = treatment is working β encouraging sign
- Stable CA 19-9 = disease is controlled β also positive
- Limitation: ~10% of people don't produce CA 19-9 (Lewis antigen negative) β in these cases, CEA or other markers are used
Ask the oncologist for the CA 19-9 trend chart β it's one of the most important indicators of how well the treatment is working, alongside the CT scans.
5 Β· TCM (Traditional Chinese Medicine) Supportive Care
Important: TCM should complement, never replace conventional chemotherapy. All TCM herbs and treatments must be reviewed by the oncologist before use β some herbs can interact with chemotherapy drugs or affect liver/kidney function. TCM's role in this context is purely supportive care: managing side effects, improving quality of life, and strengthening the body's resilience during chemo.
5.1 Evidence Base for TCM in Pancreatic Cancer
- A 2022 systematic review found TCM combined with chemotherapy improved quality of life, reduced chemo side effects, and showed signals of prolonged survival in advanced pancreatic cancer patients. source
- PHY906 β a modernized herbal compound (based on traditional formula Huang Qin Tang) tested in gemcitabine-refractory pancreatic cancer patients β showed good tolerability, reduced GI toxicity, and signals of prolonged survival. source
- A multicenter prospective cohort study is underway in China evaluating integrated TCM + Western medicine for advanced pancreatic cancer survival and quality of life. source
- TCM is best used at each stage of treatment β before chemo (strengthen body), during chemo (manage side effects), after chemo (recovery). source
5.2 How TCM Can Help During Chemotherapy
TCM During Chemo β Specific Applications
| Chemo Side Effect | TCM Approach |
|---|
| Nausea & Vomiting | Acupuncture at PC6 (Neiguan) point β well-researched, ASCO-endorsed for chemo-induced nausea. Ginger (ηε§) tea. Formulas containing Ban Xia (Pinellia) and Chen Pi (Tangerine peel). |
| Fatigue | Astragalus (Huang Qi / ι»θͺ) β the most studied TCM herb for cancer-related fatigue. Improves energy and immune function. Ginseng (Ren Shen) for Qi deficiency. |
| Neutropenia | Astragalus-based formulas β some evidence of WBC-boosting effects. Must coordinate with G-CSF injections β don't double-up without oncologist knowledge. |
| Diarrhea | Shen Ling Bai Zhu San (εθη½ζ―ζ£) β classic formula for spleen Qi deficiency with diarrhea. Bai Tou Weng Tang for heat-type diarrhea. |
| Loss of appetite | Li Zhong Wan or Xiang Sha Liu Jun Zi Tang β formulas to strengthen spleen and improve appetite. Acupuncture at ST36 (Zusanli). |
| Neuropathy | Acupuncture shows evidence for chemo-induced peripheral neuropathy. Herbal soaks with Dang Gui, Chuan Xiong, Hong Hua. |
| Mood & Sleep | Acupuncture for anxiety and insomnia. Dan Shen (Salvia) for blood circulation and calming. Mind-body practices. |
| Overall resilience | Individualized TCM formula prescribed by a qualified TCM physician based on tongue/pulse diagnosis. The "right" formula changes throughout the chemo cycle. |
5.3 TCM Resources in Singapore
| Center | Services | Notes |
|---|
| Eu Yan Sang TCM Clinic | Dedicated Cancer Care & Oncology Support program. Physician He Qiu Ling specializes in integrative cancer care. Multiple locations (Chinatown Point, others). link | Most established TCM clinic network in SG. Experienced in working alongside cancer patients. English-speaking physicians available. |
| NCCS Integrative Oncology Clinic | Evidence-based complementary therapies: acupuncture, mind-body therapies, psychological support. Dr Gary Deng (integrative medicine leader) spoke at NCCS symposium Feb 2025. link | Western-trained + TCM integration. Part of NCCS β so TCM is coordinated directly with the oncology team. Best option for ensuring no herb-drug interactions. |
| Parkway Cancer Centre | Comprehensive TCM integration program. Joint talks with Eu Yan Sang. Board-certified integrative oncologists. Herb safety assessments. link | Private hospital, faster access. TCM herb safety checks done in-house. |
| Renhai (δ»ζ΅·) TCM / Other TCM clinics | Various independent TCM practitioners in SG with oncology support experience | Look for practitioners registered with the TCM Practitioners Board (TPB) Singapore β the official regulatory body. Check for cancer care experience specifically. |
Best practice for TCM integration: The ideal approach is to have TCM prescribed through the NCCS Integrative Oncology Clinic or a TCM physician who communicates directly with the oncologist. This ensures: (1) no herb-drug interactions, (2) liver/kidney function is monitored, (3) the TCM formula is adjusted based on the chemo cycle phase, (4) everything is documented in one medical record.
5.4 TCM Precautions During Chemotherapy
Herbs to avoid or use with caution during chemo:
- St. John's Wort β interacts with many chemo drugs (CYP3A4 enzyme induction)
- High-dose antioxidants (vitamin E, selenium, green tea extract in high doses) β may reduce chemo effectiveness. Normal dietary amounts are fine.
- Grapefruit β affects metabolism of many drugs including some chemo agents
- Blood-thinning herbs (Danshen, Ginkgo, high-dose fish oil) β increased bleeding risk with low platelets
- Any "anti-cancer" herbal remedies from unverified sources β some contain undisclosed pharmaceutical ingredients or heavy metals
- Immune-boosting herbs (high-dose Echinacea, Reishi mushroom) β theoretical concern of interfering with chemo's mechanism. Discuss with oncologist.
Rule: If the oncologist hasn't approved it, don't take it. Full stop.
6 Β· Other Supportive Measures
6.1 Psychological & Emotional Support
A 6-month intensive chemo battle is as much a mental challenge as a physical one. Research shows that psychological well-being directly impacts treatment outcomes and quality of life.
| Approach | Details |
|---|
| Professional counseling | NCCS has a psycho-oncology service. Many cancer centers offer free counseling. HK: Queen Mary Hospital is ESMO-accredited for integrated oncology & palliative care, which includes psychological support. source |
| Support groups | Pancreatic Cancer Action Network (PanCAN), Cancer Research UK forum, Singapore Cancer Society support groups. Connecting with others going through the same thing is powerful. |
| Mindfulness & meditation | Apps: Headspace, Calm, Insight Timer. NCCS Integrative Oncology offers mind-body therapies. ASCO-endorsed for cancer-related anxiety. source |
| Journaling | Track symptoms, side effects, mood, questions for the oncologist. Helps both emotional processing and medical management. |
| Family & friends | The friend's positive spirit is a major asset. Maintain social connections β isolation worsens outcomes. Video calls if in-person visits aren't possible during nadir periods. |
6.2 Physical Activity & Exercise
Counterintuitively, exercise during chemotherapy improves outcomes. Research shows cancer patients who exercise during chemo have less fatigue, better tolerance, and potentially better treatment response.
- During good days (days 10-14): 20-30 minute walks, gentle yoga, stretching
- During bad days (days 3-9): Even 5-10 minutes of light movement helps. Bed exercises, ankle pumps, gentle range of motion.
- Avoid: Heavy lifting (port site healing), contact sports (bleeding risk), swimming until port site fully healed
- Goal: Don't aim for pre-cancer fitness levels. Aim for "as much movement as tolerable" β consistency beats intensity.
6.3 Practical Preparation Checklist
Before Chemo Starts (next 2 weeks):
- Get a thermometer (digital, for daily temp checks) β this is non-negotiable
- Stock up on Imodium (loperamide) β carry at all times
- Buy electrolyte drinks (Pocari, 100 Plus, or oral rehydration salts)
- Prepare soft, easy-to-eat foods β soups, congee, smoothies, yogurt
- Get alcohol hand gel for every room
- Buy masks (surgical grade) for clinic visits and crowded places
- Install a symptom tracking app or get a notebook
- Get ginger products (tea, candies) for nausea
- Get plastic utensils (metal tastes bad during chemo)
- Prepare loose, comfortable clothing that's easy to put on for clinic days
- Get gloves for handling cold items from fridge (oxaliplatin cold sensitivity)
- Arrange transportation for clinic days β don't drive yourself after chemo
- Identify the 24-hour oncologist hotline number β save in phone, post on fridge
- Get nutritional supplement drinks (Ensure, Fortisip, Resource)
- Discuss pancreatic enzyme replacement (Creon) with oncologist
6.4 Financial & Administrative Preparation
- Insurance review: Check what's covered β chemo drugs, G-CSF injections, hospital visits, home nursing. Pegfilgrastim alone can cost USD 3,000-6,000/injection.
- Medical leave: Arrange extended medical leave from work β 6 months minimum. The friend mentioned retirement, so this may not apply.
- Caregiver arrangement: Someone needs to be present during home infusion (days 1-3) and nadir period (days 5-10). Rotate family members if possible.
- Medical records organization: Keep all lab results, scan reports, chemo treatment summaries in one folder. This is also critical if seeking a second opinion from Singapore.
7 Β· What Singapore's Medical Field Can Contribute
This is where you, buddy, can make a real difference. Singapore has specific capabilities that complement what the friend is receiving in Hong Kong. Here's what can be done from Singapore β in parallel with the HK treatment, not instead of it.
7.1 Molecular Profiling β The #1 Priority
Critical action item: Before or early in the chemo course, the tumor tissue from the umbilical cyst biopsy (and/or the pancreatic tumor biopsy) must be sent for molecular profiling. This is the single most important thing that determines future treatment options. If the HK oncologist hasn't ordered this, it needs to be requested.
What needs to be tested:
| Test | Why It Matters | SG Capability |
|---|
| KRAS mutation status | >90% of PDAC tumors have KRAS mutations. Determines eligibility for daraxonrasib (RMC-6236) β FDA Breakthrough Therapy, showed complete response in a patient with peritoneal metastases. Phase 3 trial completed enrollment. source | Available at NCCS, NCIS, and private labs (Quest, Pathnostics). SG may have KRAS inhibitor trials enrolling. |
| BRCA 1/2 status | If positive β eligible for olaparib (PARP inhibitor) β FDA-approved maintenance therapy for BRCA-mutated metastatic PDAC | Standard testing at NCCS, NUH, private hospitals |
| PD-L1 / MSI status | Determines immunotherapy eligibility (rare in PDAC but worth checking β ~1% are MSI-high) | Available at major SG centers |
| NTRK fusion | If positive β eligible for larotrectinib/entrectinib (tumor-agnostic therapy). Very rare (<1%) but life-changing if positive. | Available at NCCS |
| Comprehensive genomic profiling | Panel testing (FoundationOne, Tempus, or similar) covers hundreds of genes β may identify unexpected treatment options or trial eligibility | Available through NCCS research program and private oncology (OncoCare, Parkway) |
How to arrange from SG: If the friend's HK pathology blocks (tissue samples) can be shipped to Singapore, NCCS molecular pathology lab can run the profiling. Alternatively, HK labs can run the tests and SG oncologists can interpret results for second opinion. The friend should ask their HK oncologist: "Can we send the biopsy tissue for comprehensive molecular profiling including KRAS, BRCA, PD-L1, MSI, and NTRK?"
7.2 NCCS SPRinT Second Opinion β Peritoneal Specialists
The SPRinT (Sarcoma, Peritoneal and Rare Tumours) team at NCCS is one of Asia's most experienced peritoneal cancer centers:
- 500+ CRS/HIPEC procedures since 2001 β one of the most experienced in Asia source
- Offers PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) β one of few centers in Asia source
- Weekly multidisciplinary tumor board for peritoneal disease
- Key specialists: A/Prof Claramae Chia (surgical oncologist), Dr Tham Chee Kian (medical oncology), Dr Matthew Ng (GI oncology head)
How to arrange a second opinion:
- Friend gathers all records: CT/MRI/PET-CT scans, pathology reports (including umbilical cyst biopsy), blood work (CA 19-9 trend), proposed treatment plan
- Records sent to NCCS International Patient Liaison (electronic transfer possible)
- NCCS SPRinT team reviews at their weekly tumor board
- Recommendations provided: (a) Is the current chemo regimen optimal? (b) Is PIPAC suitable for the peritoneal disease? (c) Is there a trial the patient is eligible for? (d) After 6 months of chemo, would conversion surgery + HIPEC be considered?
Timing: The second opinion can be sought now β it doesn't need to wait for the chemo to finish. NCCS can review the case in parallel and provide recommendations that the HK oncologist can consider. The ideal window for PIPAC evaluation is during or after chemo β if the peritoneal disease responds to chemo, PIPAC may be used to "mop up" residual peritoneal deposits.
7.3 PIPAC β A Singapore-Specific Advantage
Why PIPAC Matters for This Case
PIPAC delivers chemotherapy directly into the abdominal cavity as a pressurized aerosol β targeting exactly where the cancer has spread (peritoneum). Key points:
- Minimally invasive β laparoscopic keyhole surgery, not open
- Can be repeated (typically every 6 weeks)
- Can be combined with systemic chemo simultaneously
- Better tissue penetration than IV chemo for peritoneal deposits
- NCCS Singapore has this capability β not widely available in Hong Kong
- A case report of a PDAC patient treated with systemic chemo + PIPAC showed promising results source
Strategic opportunity: The friend's treatment plan is 6 months systemic chemo β reassess. PIPAC could be the "next step" after chemo β if peritoneal disease persists after systemic treatment, PIPAC directly targets those remaining deposits. NCCS Singapore is the place to evaluate this. This is the single biggest unique contribution Singapore can make to this case.
7.4 Clinical Trials β Singapore Access
Singapore cancer centers run active clinical trials. For this case, the most relevant areas:
- KRAS inhibitor trials β daraxonrasib (RMC-6236) Phase 3 RASOLUTE 302 completed enrollment, but next-generation KRAS drugs (INCB161734 for KRAS G12D) are entering trials. Presented at ASCO GI 2026. source
- NCCS current trials β check NCCS current clinical trials for pancreatic cancer studies enrolling
- NCIS trials β National University Hospital also runs oncology trials
- Cross-border trial participation: Some trials allow patients to receive treatment at a SG site while living primarily in HK β depends on trial protocol. Worth asking.
- Molecular eligibility: Many trials require specific molecular profiles (e.g., KRAS G12C, KRAS G12D, BRCA+). This is why molecular profiling is the #1 priority β without knowing the mutation status, trial eligibility can't be assessed.
7.5 Integrative Oncology Support β From Singapore
While the friend is in HK undergoing chemo, Singapore's integrative oncology resources can provide:
| Resource | How It Helps |
|---|
| NCCS Integrative Oncology Clinic | Can provide guidance on evidence-based complementary therapies, acupuncture protocols, and mind-body practices. Virtual consultation may be possible. source |
| Eu Yan Sang TCM Cancer Care | TCM physicians experienced in chemo support. Can prescribe customized herbal formulas to manage side effects. Formula can be shipped to HK. source |
| Parkway Cancer Centre Integrative Program | Comprehensive TCM integration with herb safety assessment. source |
| Singapore Cancer Society | Support services, counseling, financial assistance programs, support groups |
7.6 What You (Buddy) Can Specifically Do From Singapore
-
Coordinate the NCCS second opinion
Contact NCCS International Patient Liaison on behalf of the friend. Help gather and transmit medical records from HK. The friend may be fatigued from chemo β you can be the logistics coordinator.
-
Research PIPAC eligibility pathway
Specifically ask NCCS SPRinT team: "Given confirmed peritoneal spread from pancreatic cancer, would PIPAC be considered after or during systemic chemotherapy? What are the criteria?" This is the unique value-add Singapore provides.
-
Monitor clinical trial landscape
Set up alerts for pancreatic cancer clinical trials in Singapore. Check NCCS and NCIS trial pages monthly. When new KRAS-targeted or immunotherapy trials open, notify the friend's HK oncologist. The oncologist can then evaluate eligibility.
-
Arrange TCM consultation
Book a consultation with Eu Yan Sang's cancer care physician or NCCS Integrative Oncology. Have the TCM physician review the chemo regimen and prescribe supportive formulas. Ship herbs to HK. Ensure the HK oncologist is informed of all TCM supplements.
-
Be the information bridge
You have access to both SG and HK medical information. Help the friend understand treatment options, prepare questions for the oncologist, and translate medical jargon. Sometimes just having someone who understands the landscape is the biggest help.
-
Prepare for the post-chemo decision point
At ~6 months, the friend will face a major decision: surgery or not? Having the NCCS SPRinT second opinion already in hand means both options (HK surgery or SG PIPAC/surgery) can be considered with full information. Start this process now, not at month 6.
8 Β· Updated Questions to Ask the Oncologist
For the HK oncologist β before chemo starts:
"What is the exact chemo regimen? Is it FOLFIRINOX or modified FOLFIRINOX? What dose modifications are planned?"
"Has the umbilical cyst tissue been sent for molecular profiling (KRAS, BRCA, PD-L1, MSI, NTRK)? If not, can this be ordered urgently before chemo starts?"
"What is the plan for G-CSF support? Pegfilgrastim or filgrastim? When will it be administered?"
"What is the baseline CA 19-9 level? Will it be tracked before each cycle?"
"When will the first response assessment CT scan be done? After cycle 4?"
"What are the criteria for conversion surgery after 6 months? What response is needed to make the tumor operable?"
"Are there any clinical trials in Hong Kong that I would be eligible for β especially KRAS-targeted therapy?"
"Would you support a second opinion from NCCS Singapore's SPRinT team for peritoneal disease evaluation?"
"Can I take TCM herbal supplements during chemo? Are there any you specifically recommend or advise against?"
"What is the 24-hour emergency contact number? When exactly should I call vs. go to A&E?"
For the NCCS Singapore second opinion:
"Based on the confirmed peritoneal spread (umbilical metastasis), is PIPAC a viable option β either during or after systemic chemotherapy?"
"After 6 months of conversion chemotherapy, would this patient be a candidate for CRS + HIPEC if the peritoneal disease responds?"
"Are there any clinical trials at NCCS that a metastatic PDAC patient with peritoneal spread would be eligible for?"
"What is the recommended molecular profiling panel β and can NCCS run this on tissue shipped from HK?"
"Can PIPAC and systemic chemotherapy be done simultaneously? What is the schedule?"
"If PIPAC is recommended, how many sessions would be expected, and what is the treatment schedule?"
"Can the NCCS Integrative Oncology Clinic provide TCM guidance that coordinates with the HK oncologist's treatment plan?"
9 Β· Updated HK vs SG Comparison
| Dimension | ππ° Hong Kong (Current Treatment) | πΈπ¬ Singapore (Support & Second Opinion) |
|---|
| Primary Treatment |
FOLFIRINOX chemo β 12 cycles over 24 weeks β
|
Second opinion + PIPAC evaluation + trial access |
| Peritoneal Expertise |
QMH has HBP surgery expertise; peritoneal-specific program unclear |
NCCS SPRinT: 500+ CRS/HIPEC, PIPAC program β clear advantage |
| PIPAC |
Available at Gleneagles HK (private) source; also a PIPAC trial at HKU (NCT06367270) source |
Available at NCCS + NCIS β established programs |
| Clinical Trials |
HKU/CUHK run trials; KRAS trial access unclear |
NCCS + NCIS active trials; KRAS-targeted trials potentially available |
| Molecular Profiling |
Available β must be requested if not already ordered |
Available at NCCS; can run on shipped tissue from HK |
| Integrative Oncology / TCM |
Available in HK (CUHK has TCM school) |
NCCS Integrative Oncology Clinic, Eu Yan Sang, Parkway β coordinated with oncology team |
| Conversion Surgery |
QMH HBP surgery team can operate if tumor becomes resectable |
SPRinT team can perform surgery + HIPEC if peritoneal disease needs surgical treatment |
| Cost |
HK public hospital β covered for residents |
International patient rates; private options available |
| Best Role |
Primary treatment delivery β chemo cycles, port management, acute care |
Specialist consultation β peritoneal expertise, PIPAC, trials, integrative care, post-chemo surgical planning |
The optimal strategy: HK for primary treatment (chemo delivery, port management, acute care β all handled locally). SG for specialist overlay (NCCS second opinion now β PIPAC evaluation β trial monitoring β post-chemo surgical planning if needed). The two systems complement each other perfectly. You (buddy) are the bridge between them.
10 Β· Mainland China β Medical Capabilities & Treatment Options
China's medical system has advanced rapidly, particularly in oncology. Several areas are directly relevant to this case: HIPEC/CRS expertise, the world's first CAR-T therapy for solid tumors (approved 2026), cutting-edge TCM-integrated cancer care, and cross-border access from Hong Kong via the Greater Bay Area.
10.1 CAR-T Cell Therapy β World First in China
CLDN18.2-Targeted CAR-T (Satri-cel / CT041) π World First β Approved in China 2026
In April 2026, China approved the world's first CAR-T cell therapy for solid tumors β a groundbreaking development. Here's why it matters for pancreatic cancer:
- Satri-cel (satricabtagene autoleucel / CT041), developed by CARsgen Therapeutics (Shanghai) β targets CLDN18.2, a protein expressed in gastrointestinal cancers including pancreatic cancer
- The pivotal Phase II trial (CT041-ST-01, NCT04581473) showed median overall survival of 7.92 months vs 5.49 months in heavily pretreated patients who had run out of options source
- Disease control rate of 75.5% in gastrointestinal tumors, with complete tumor regression observed in some heavily pretreated patients, including pancreatic cancer source
- Phase Ib studies are ongoing specifically in advanced pancreatic cancer, plus adjuvant therapy studies source
- Expected to become clinically available in China in first half of 2026 source
Why this matters: This is the first CAR-T therapy ever approved for solid tumors (previous CAR-T successes were only in blood cancers). Pancreatic cancer is one of the targeted indications. While the primary approval is for gastric/gastroesophageal junction cancer, pancreatic cancer trials are actively enrolling. A patient whose tumor expresses CLDN18.2 could potentially access this therapy through clinical trials in China β an option not available in HK or SG.
Eligibility requirement: The tumor must be tested for CLDN18.2 expression (immunohistochemistry). This is NOT routinely tested in HK or SG β it's primarily a Chinese-developed biomarker. If pursuing the China pathway, request CLDN18.2 testing alongside KRAS/BRCA profiling.
10.2 Leading Chinese Cancer Centers
Fudan University Shanghai Cancer Center (FUSCC) β National Pancreatic Cancer Leader
- Affiliated with Fudan University, Shanghai β one of China's top cancer hospitals
- Has a dedicated Pancreatic Surgery Department β a national key clinical specialty focused exclusively on pancreatic cancer and neuroendocrine tumors source
- Has a Shanghai Key Laboratory of Pancreatic Cancer β one of the few dedicated pancreatic cancer research labs in China source
- Developed a proprietary 6-gene pancreatic cancer detection kit β precision diagnostics breakthrough source
- Performs CRS + HIPEC β early adopter in mainland China (since ~2010) source
- Equipped with proton/carbon ion therapy, NGS molecular subtyping, robotic surgery, and immunotherapy combinations source
- International patient services available; accepts foreign patients
Other Major Chinese Centers
| City | Key Hospitals | Strengths for This Case |
|---|
| Shanghai | FUSCC (above), Zhongshan Hospital, Ruijin Hospital | Pancreatic cancer specialty, HIPEC, CAR-T trials, molecular profiling, TCM integration |
| Beijing | Peking University Cancer Hospital, 301 Hospital, Guang'anmen Hospital (TCM) | Guang'anmen is a top TCM cancer center. 301 Hospital has advanced oncology. Clinical trial hub. |
| Guangzhou | Sun Yat-sen University Cancer Center, Fudan Hospital Guangzhou | Close to HK (~2hr by high-speed rail). Strong GI oncology. High international patient volume. |
| Shenzhen | HKU-Shenzhen Hospital | Operates under HKU management standards. MDT oncology for pancreatic cancer. Most accessible from HK β same healthcare system standards. source |
10.3 TCM-Integrated Cancer Care β China's Unique Strength
China is the world leader in integrative TCM + Western oncology. This is where mainland China offers something neither HK nor SG can fully match β decades of systematic research and clinical integration of TCM alongside chemotherapy:
- Guang'anmen Hospital (Beijing) β China Academy of Chinese Medical Sciences. One of the nation's top TCM hospitals with a dedicated oncology department. source
- Shuguang Hospital (Shanghai) β Shanghai University of TCM. Specializes in integrative medicine for chronic diseases including cancer source
- A multicenter prospective cohort study evaluating TCM + Western medicine for advanced pancreatic cancer is ongoing in China β institutional coordination that SG/HK cannot match in scale source
- Chinese hospitals routinely integrate TCM into chemotherapy protocols β managing nausea, fatigue, neutropenia, and quality of life with individualized herbal prescriptions adjusted throughout the chemo cycle
- Some Chinese research explores CAR-T combined with TCM β an innovative combination approach unique to China source
- Brucea javanica oil emulsion β a TCM-derived injectable used as adjuvant therapy in Chinese hospitals, with systematic reviews showing safety and efficacy signals when combined with chemotherapy source
10.4 Greater Bay Area Cross-Border Healthcare
Most practical pathway from HK: The HKU-Shenzhen Hospital is the easiest cross-border option for the friend. It operates under University of Hong Kong management standards, is physically in Shenzhen (~30 min from HK by high-speed rail), and excels in multidisciplinary oncology for pancreatic cancer. This means the friend could access mainland China capabilities without leaving the HKU healthcare system.
GBA Cross-Border Developments (2025-2026):
- HKU launched the "Healthy GBA" platform (healthygba.hku.hk, live Oct 2025) β cross-border healthcare information for HK residents seeking treatment in the Greater Bay Area source
- In Feb 2026, HK Secretary for Health Prof. Lo Chung-mau led a delegation to Shenzhen to deepen cross-border healthcare collaboration source
- "Five connections" system being developed to ease cross-border access to quality care source
- HMG + OncoCare Pan-Asian cooperation agreement (July 2026) enables cross-border cancer second opinions across the region source
10.5 What Mainland China Specifically Offers for This Case
| Capability | Details | Relevance |
|---|
| CLDN18.2 CAR-T therapy | World's first solid tumor CAR-T β approved 2026, pancreatic cancer trials enrolling | β Unique to China β not available in HK or SG. Requires CLDN18.2 testing. Could be a post-chemo option if standard treatment is insufficient. |
| FUSCC pancreatic expertise | National key specialty, dedicated pancreatic cancer lab, 6-gene detection kit, HIPEC | World-class pancreatic cancer center. Second opinion option alongside NCCS Singapore. |
| TCM-integrated oncology | Decades of systematic TCM + chemo integration research, dedicated TCM cancer hospitals | Deepest TCM expertise for chemo side effect management. Can provide customized herbal protocols. |
| Clinical trial volume | China runs more oncology trials than any Asian country β KRAS, CAR-T, immunotherapy, vaccine trials | Broader trial options, especially for later-line or post-chemo scenarios. |
| Proton/carbon ion therapy | Available at major Chinese cancer centers β advanced radiation not widely available in HK/SG | Potentially relevant if localized radiation is needed after chemo response. |
| HKU-Shenzhen Hospital | HKU-managed, GBA cross-border, MDT pancreatic oncology | Easiest access point from HK β same management standards, physically in Shenzhen. |
10.6 Practical Pathway: Accessing Mainland China Treatment
-
Start with HKU-Shenzhen Hospital
The friend's HK oncologist can refer to HKU-Shenzhen Hospital for consultation. This is the simplest cross-border pathway β same university system, managed to HK standards. The hospital can evaluate whether mainland China capabilities (CAR-T, TCM integration, clinical trials) are relevant to the case.
-
Request CLDN18.2 testing
If the friend is interested in the CAR-T pathway, request CLDN18.2 immunohistochemistry on the biopsy tissue. This testing is routine in Chinese hospitals but may need to be specifically requested in HK. Without CLDN18.2 expression, CAR-T is not an option.
-
Explore FUSCC second opinion
Fudan University Shanghai Cancer Center accepts international patients. Their pancreatic cancer team can provide a second opinion alongside the NCCS Singapore opinion β two perspectives from two world-class centers. Shanghai is a ~2.5 hour flight from HK.
-
TCM consultation with Chinese specialists
If the friend wants the deepest TCM-integrated cancer care, Guang'anmen Hospital (Beijing) or Shuguang Hospital (Shanghai) are the leading centers. They can provide customized herbal protocols coordinated with the chemotherapy regimen. Video consultations may be possible for initial assessment.
-
Monitor CAR-T trial enrollment
The satri-cel (CT041) pancreatic cancer Phase Ib study is ongoing. Check ClinicalTrials.gov for enrollment status. If the friend's tumor is CLDN18.2-positive and standard chemo is insufficient, this could be a next-line option available exclusively in China.
10.7 Three-Region Comparison: HK vs SG vs Mainland China
| Capability | ππ° Hong Kong | πΈπ¬ Singapore | π¨π³ Mainland China |
|---|
| Primary Chemo |
β
FOLFIRINOX β current treatment |
β
Available |
β
Available β FUSCC has national pancreatic specialty |
| CRS + HIPEC |
Limited in public system |
β
NCCS SPRinT (500+ procedures) |
β
FUSCC + others (early adopters since 2010) |
| PIPAC |
β
Gleneagles HK (private) + HKU trial |
β
NCCS + NCIS |
Emerging β limited centers |
| CAR-T (solid tumor) |
β Not available |
β Not available |
β World first β approved 2026, pancreatic trials enrolling |
| KRAS inhibitor trials |
Limited |
Potentially at NCCS/NCIS |
Active trial programs |
| TCM integration |
Limited (CUHK TCM school) |
β
NCCS Integrative Oncology, Eu Yan Sang |
β World leader β systematic, decades of research |
| Molecular profiling |
β
Available |
β
Available β can run on shipped tissue |
β
Available + CLDN18.2 testing (unique biomarker) |
| Proton/carbon ion therapy |
Limited |
Available at private centers |
β
Multiple centers |
| Cross-border ease from HK |
β |
~4hr flight |
β HKU-Shenzhen: 30min by rail β same HKU system |
| Cost |
Public: covered for HK residents |
International patient rates |
Generally lower cost; public/private options |
| Language |
Cantonese, English, Mandarin |
English, Mandarin |
Mandarin primarily; major hospitals have English services |
Strategic summary β three-region approach:
ππ° Hong Kong = Primary treatment (chemo delivery, port management, acute care). The friend is already in good hands here.
πΈπ¬ Singapore = Specialist overlay (NCCS SPRinT second opinion, PIPAC evaluation, trial monitoring, integrative oncology, post-chemo surgical planning). You (buddy) coordinate this from SG.
π¨π³ Mainland China = Next-generation options (CAR-T therapy if CLDN18.2+, deepest TCM-integrated cancer care, FUSCC pancreatic expertise, broader trial access). Most accessible via HKU-Shenzhen Hospital β same HKU system, 30 min from HK.
Best approach: Don't choose one β use all three in parallel. The friend's HK oncologist handles primary treatment. NCCS Singapore provides peritoneal specialist overlay. Mainland China provides the CAR-T pathway and TCM integration if needed. The key to unlocking all three is molecular profiling (KRAS, BRCA, CLDN18.2, MSI, NTRK) β get this done early.
11 Β· Key Sources & References
- FOLFIRINOX vs Gemcitabine for Metastatic Pancreatic Cancer β NEJM
- FOLFIRINOX regimen details (eviQ protocol) β eviQ
- Conversion Surgery after FOLFIRINOX β PMC
- Conversion Surgery Survival Outcomes β Anticancer Research
- FOLFIRINOX Neoadjuvant Resectability β Annals of Surgery
- Conversion Surgery Predictive Factors β PubMed
- Sister Mary Joseph Nodule β PMC
- Elastomeric Pump Home Infusion Guide β MSKCC
- Chemotherapy at Home β MD Anderson
- Pegfilgrastim (G-CSF) β StatPearls / NCBI
- ASCO G-CSF Guideline Update 2025 β JCO
- Ports, PICC Lines and Pumps β Colontown University
- Pancreatic Cancer Side Effects Management β Let's Win PC
- Side Effects Guide 2026 β HOncology
- Nutritional Interventions During Chemo β PMC
- Nutrition for Pancreatic Cancer β Lustgarten Foundation
- Long-term Effects of Chemo β NPCF
- TCM for Pancreatic Cancer (systematic review) β Frontiers in Pharmacology
- TCM + Metastatic Pancreatic Cancer β Dr. Alexander Heyne
- TCM + Western Medicine for PDAC (study protocol) β PubMed
- TCM Advances in Pancreatic Cancer β PMC
- Eu Yan Sang TCM Cancer Care β Eu Yan Sang
- Eu Yan Sang Post-Cancer Recovery β Eu Yan Sang
- NCCS Integrative Oncology β NCCS
- NCCS: Can TCM Be Part of Cancer Care? β NCCS
- Parkway Cancer Centre + TCM β Parkway
- TCM After Chemotherapy Safety Guide β TCM Clinics SG
- NCCS SPRinT β NCCS
- NCCS PIPAC β NCCS
- NCCS Current Clinical Trials β NCCS
- KRAS Inhibitor Breakthrough β MSKCC
- ASCO GI 2026 β KRAS G12D Inhibitor β Let's Win PC
- 2026 Pancreatic Cancer Treatment Advances β HOncology
- QMH ESMO Accreditation β ESMO
- China CAR-T for Solid Tumors (world first) β PR Newswire
- CAR-T in China: Innovations & Challenges β PMC
- Satri-cel Phase II Results β OncoDaily
- Solid Tumor CAR-T Approved in China β Inside Precision Medicine
- CARsgen CT041 Research β CARsgen
- Fudan University Shanghai Cancer Center β FUSCC
- FUSCC Pancreatic Surgery β MedBridgeNZ
- HIPEC in Mainland China β PMC
- Cancer Treatment in China: City Comparison β To China Care
- China Top Hospitals 2026 Guide β To China Care
- Cancer Treatment in Shenzhen β To China Care
- HKU-Shenzhen Hospital β HKU-SZH
- HKU GBA Cross-Border Healthcare β HKU
- GBA Healthcare Collaboration Feb 2026 β Greater Bay Healthcare
- Gleneagles HK PIPAC β Gleneagles HK
- HKU PIPAC Trial (NCT06367270) β PMC
- Pancreatic Cancer Treatment in China Overview β PMC
- Daraxonrasib Pan-RAS Inhibitor β Nature Reviews
β οΈ MEDICAL DISCLAIMER
This report was compiled from publicly available medical literature and institutional websites as of July 2026. It is for informational purposes only and does NOT constitute medical advice, diagnosis, or treatment recommendations. The patient must consult with qualified oncologists for all medical decisions. Every case is unique. General statistics cited here do not predict individual outcomes. TCM and complementary therapies should only be used alongside conventional treatment with the oncologist's approval. Treatment availability, clinical trial enrollment, and institutional details may change β verify directly with the relevant institutions before making any decisions.